Effect at 6 Months of Renal Denervation in Chronic Heart Failure d'Insuffisance Cardiaque

NCT ID: NCT02471729

Last Updated: 2016-10-19

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-01-31
• Study Completion Date: 2018-01-31

Brief Summary

Management of chronic heart failure (CHF) is a major public health problem. It is associated with high mortality, frequent hospitalization and represents a large cost to the health care system. Both pharmacological and non-pharmacological intervention haven't shown to be effective in reducing morbidity and mortality of these patients when able to modulate the activity of neuro-hormonal systems among them the sympathetic nervous system. Recent data have emphasized the potential role of sympathetic renal denervation in patient with hypertension. CHF per se but even more CHF associated with comorbity lead to significant increase level of sympathetic tone. This is largely induced by autonomic dysfunction such as chemo or baroflex abnormalities. These patients usually suffer from conditions which do not allow upgrading and adapting drugs to their sympathetic condition. Hence CHF patient with chronic kidney disease, anemia or both have markedly high sympathetic activity and cannot be exposed to higher level of RAS Blockers or beta blocker due to their renal dysfunction, they thus remain with an elevated sympathetic activity worsening symptoms and prognosis. Chronic heart failure affects around 100 million people worldwild imposing a significant burden on health care system throughout the world. Even though symptoms are improved by heart failure therapy, they remain significantly disabling for many patients. Chronic over activation of the sympathetic nervous system is a major component of heart failure and involves efferent and afferent pathways between brain and many organs. A new therapy directly targeting nerve traffic-renal artery denervation- has been shown to be effective in drug resistant hypertension, with an average drop in blood pressure of 33/12 mm hg.

The cardiologists team of the private hospital Arnault Tzanck is willing therefore to conduct a study in 12 patients with chronic systolic heart failure undergoing bilateral renal denervation with an intensive protocol of observation and assessment compring a 3 day hospital stay post procedure 3 and 6 months of regular outpatient follow-up.

Detailed Description

Renal denervation is a new interventional cardiology technique that involves using a catheter and a femoral artery, inserting an RF probe that will destroy the nerve fibers in contact with the wall of the renal artery with a very small electric current.

The method utilizes the energy emitted by a miniaturized device positioned at the end of a catheter. This catheter is positioned in the arteries going to the kidneys.

Sympathetic overactivation, is reduced by renal denervation in drug-resistant hypertension. Several studies conducted in patients without heart failure showed that renal denervation reduces left ventricular hypertrophy beyond its only effect on blood pressure.

Chronic over activation of the sympathetic nervous system is a major component of heart failure and involves efferent and afferent pathways between brain and many organs.

The purpose of this Clinical investigation is to evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with chronique heart failure.

All patients will be on stable maximal tolerated pharmacological therapy for HFC prior to denervation.

After the procedure all patients will be monitored as inpatients for 3 days so that hemodynamic disturbances could be identified. Baseline measurements, including BNP, echo Doppler VO2 and six minutes walk test will be repeated before discharge from hospital.

After discharge patients will be followed up weekly for 4 weeks and then after 3 and 6 months. At the end of the study, bnp, echo Doppler Vo2 and six minutes walk test will be repeated, they also will be asked to categorize themselves as feeling worse, the same, or better in comparison to their preprocedural state.

Conditions

Chronic Heart Failure

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Renal Denervation

patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy

Group Type: EXPERIMENTAL

EnligHTN™ Renal Denervation System

Intervention Type: DEVICE

The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.

Interventions

EnligHTN™ Renal Denervation System

The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.

Intervention Type: DEVICE

Other Intervention Names

EnligHTN™ Renal Artery Ablation Catheter; EnligHTN™ RF Generator; EnligHTN™ Guiding Catheter

Eligibility Criteria

Inclusion Criteria

• Stable chronic heart failure
• NYHA III-IV
• LV EF <35 assessed by ultrasound
• EGFR> 45ml / min / 1.73m2
• Optimal therapeutic treatment
• IMC : 17-24

Exclusion Criteria

• significant renovascular abnormalities such as renal artery stenosis> 30%.
• renal angioplasty history, renal denervation, stent placement
• hemodynamically significant valvular heart disease
• an active systemic infection.
• renal artery of <4 mm.
• coagulation abnormalities.
• kidney transplant or is waiting for a kidney transplant.
• life expectancy of less than 12 months (seatle score).
• femoral-iliac atherosclerotic

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott Medical Devices

INDUSTRY

Sponsor Role: collaborator

Institute Arnault Tzanck, France

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jean Louis LLORET, MD

Role: PRINCIPAL_INVESTIGATOR

Private hospital Mougins Arnault Tzanck

Locations

Clinique Plein Ciel

Mougins, Alpes Maritimes, France

Countries

France

Central Contacts

Jean Louis LLORET, MD

Role: CONTACT

jl.lloret@tzanck.org

33 (0)4.97.16.65.17

Facility Contacts

Jean Louis LLORET, MD

Role: primary

Other Identifiers

P010215

Identifier Type: -

Identifier Source: org_study_id